Cargando…

Diagnostic and Prognostic Value of Soluble Syndecan-1 in Pleural Malignancies

Background. The distinction between malignant and benign pleural effusions is a diagnostic challenge today and measuring soluble biomarkers could add to the diagnostic accuracy. Syndecan-1 is a proteoglycan involved in various cellular functions and is cleaved from the cell surface in a regulated ma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mundt, Filip, Heidari-Hamedani, Ghazal, Nilsonne, Gustav, Metintas, Muzaffer, Hjerpe, Anders, Dobra, Katalin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4131558/ https://www.ncbi.nlm.nih.gov/pubmed/25147801 http://dx.doi.org/10.1155/2014/419853

Ejemplares similares

Hyaluronan and N-ERC/Mesothelin as Key Biomarkers in a Specific Two-Step Model to Predict Pleural Malignant Mesothelioma
por: Mundt, Filip, et al.
Publicado: (2013)

Syndecan-1 Overexpressing Mesothelioma Cells Inhibit Proliferation, Wound Healing, and Tube Formation of Endothelial Cells
por: Javadi, Joman, et al.
Publicado: (2021)

Novel Genes and Pathways Modulated by Syndecan-1: Implications for the Proliferation and Cell-Cycle Regulation of Malignant Mesothelioma Cells
por: Szatmári, Tünde, et al.
Publicado: (2012)

Proteome Screening of Pleural Effusions Identifies Galectin 1 as a Diagnostic Biomarker and Highlights Several Prognostic Biomarkers for Malignant Mesothelioma
por: Mundt, Filip, et al.
Publicado: (2014)

Variation in Drug Sensitivity of Malignant Mesothelioma Cell Lines with Substantial Effects of Selenite and Bortezomib, Highlights Need for Individualized Therapy
por: Szulkin, Adam, et al.
Publicado: (2013)

Syndecan-1 in Cancer: Implications for Cell Signaling, Differentiation, and Prognostication
por: Szatmári, Tünde, et al.
Publicado: (2015)

Multiplex Soluble Biomarker Analysis from Pleural Effusion
por: Javadi, Joman, et al.
Publicado: (2020)

Molecular targets and signaling pathways regulated by nuclear translocation of syndecan-1
por: Szatmári, Tünde, et al.
Publicado: (2017)

Prognostic value of midkine, syndecan-1, hyaluronan synthase-2, sestrin-1, laminin subunit alpha-4 and fibulin-3 for malignant pleural mesothelioma
por: Akgun, Hakan, et al.
Publicado: (2021)

Microenvironment-Dependent Phenotypic Changes in a SCID Mouse Model for Malignant Mesothelioma
por: Darai-Ramqvist, Eva, et al.
Publicado: (2013)

Integrative approach to cytologic and molecular diagnosis of malignant pleural mesothelioma
por: Hjerpe, Anders, et al.
Publicado: (2020)

Specific Syndecan-1 Domains Regulate Mesenchymal Tumor Cell Adhesion, Motility and Migration
por: Zong, Fang, et al.
Publicado: (2011)

Mapping the Interactome of the Nuclear Heparan Sulfate Proteoglycan Syndecan-1 in Mesothelioma Cells
por: Kumar-Singh, Ashish, et al.
Publicado: (2020)

Diagnostic and Prognostic Utility of the Extracellular Vesicles Subpopulations Present in Pleural Effusion
por: Javadi, Joman, et al.
Publicado: (2021)

Nuclear Syndecan-1 Regulates Epithelial-Mesenchymal Plasticity in Tumor Cells
por: Kumar-Singh, Ashish, et al.
Publicado: (2021)

Ex vivo evaluation of tumor cell specific drug responses in malignant pleural effusions
por: Hillerdal, Carl-Olof, et al.
Publicado: (2017)

Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions
por: Szulkin, Adam, et al.
Publicado: (2014)

The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma
por: Ak, Guntulu, et al.
Publicado: (2015)

Syndecan-1 and FGF-2, but Not FGF Receptor-1, Share a Common Transport Route and Co-Localize with Heparanase in the Nuclei of Mesenchymal Tumor Cells
por: Zong, Fang, et al.
Publicado: (2009)

Serum Expression Levels of Certain miRNAs in Predicting Diagnosis, Prognosis, and Response to Chemotherapy in Malignant Pleural Mesothelioma
por: Metintaş, Muzaffer, et al.
Publicado: (2022)

Inhibitors of cytoskeletal dynamics in malignant mesothelioma
por: Reis, Katarina, et al.
Publicado: (2020)

Cytoskeletal Organization Correlates to Motility and Invasiveness of Malignant Mesothelioma Cells
por: Keller, Maureen, et al.
Publicado: (2021)

Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin
por: Ak, Guntulu, et al.
Publicado: (2017)

Phenotype-dependent apoptosis signalling in mesothelioma cells after selenite exposure
por: Nilsonne, Gustav, et al.
Publicado: (2009)

MicroRNA and mRNA Features of Malignant Pleural Mesothelioma and Benign Asbestos-Related Pleural Effusion
por: Ak, Guntulu, et al.
Publicado: (2015)

The Role of Syndecan-1 in Cellular Signaling and its Effects on Heparan Sulfate Biosynthesis in Mesenchymal Tumors
por: Szatmári, Tünde, et al.
Publicado: (2013)

Syndecan-1 Enhances Proliferation, Migration and Metastasis of HT-1080 Cells in Cooperation with Syndecan-2
por: Péterfia, Bálint, et al.
Publicado: (2012)

Drug sensitivity profiling and molecular characteristics of cells from pleural effusions of patients with lung adenocarcinoma
por: Ötvös, Rita, et al.
Publicado: (2015)

Utility of BerEp4/calretinin and desmin/epithelial membrane antigen (EMA) dual immunocytochemical staining in effusion cytology
por: Hjerpe, Anders, et al.
Publicado: (2022)

Use of cholesterol and soluble tumour markers CEA and syndecan-2 in pleural effusions in cases of inconclusive cytology
por: Gulyas, Miklos, et al.
Publicado: (2019)

Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis
por: Tian, Long, et al.
Publicado: (2017)

Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma: An updated meta-analysis
por: Gao, Ruiyue, et al.
Publicado: (2019)

Low Soluble Syndecan-1 Precedes Preeclampsia
por: Gandley, Robin E., et al.
Publicado: (2016)

Liquid Biopsies from Pleural Effusions and Plasma from Patients with Malignant Pleural Mesothelioma: A Feasibility Study
por: Moretti, Gabriele, et al.
Publicado: (2021)

Evaluation of the Diagnostic and Prognostic Value of Syndecan-1 in Acute Leukemia Patients
por: Alghandour, Reham, et al.
Publicado: (2020)

Syndecan Family Gene and Protein Expression and Their Prognostic Values for Prostate Cancer
por: Santos, Nilton José, et al.
Publicado: (2021)

Soluble syndecan-1 and glycosaminoglycans in preeclamptic and normotensive pregnancies
por: Hassani Lahsinoui, H., et al.
Publicado: (2021)

Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis
por: Cui, Ai, et al.
Publicado: (2014)

Diagnostic Value and Prognostic Significance of Pleural C-Reactive Protein in Lung Cancer Patients with Malignant Pleural Effusions
por: Park, Do-Sim, et al.
Publicado: (2013)

Soluble syndecan-1 (CD138): is it useful as a prognostic factor in Korean patients with multiple myeloma?
por: Lee, Je-Jung
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_qdihhdfhc44icbidhjkj7342te